Trethera
Contact Us
Trethera
Contact Us
Trethera
Trethera News & Publications
Trethera News
Co-crystal 3D structure of the drug bound to the target enzyme, dCK, at the deoxycytidine binding site.
Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045
optic-neuritis-mice_20250521
Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board
AdobeStock_1027892780 (1)
Trethera To Participate in Panel Discussion and Research Poster Competition At Los Angeles Bioscience Ecosystem Summit 2025
AdobeStock_523282619 (1)
Trethera Treats a Late-Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE-515
AdobeStock_523282619 (1)
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control Immune Cell Activation That Causes Multiple Sclerosis Symptoms in Mice
Picture_trethera1
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress
View More Posts
Trethera News
Close-up of Blue Double Helix DNA Structure on a Light Blue Back
Targeting Deoxycytidine Kinase Improves Symptoms in Mouse Models of Multiple Sclerosis
AdobeStock_523282619 (1)
18 F-FAC PET Visualizes Brain-Infiltrating Leukocytes in a Mouse Model of Multiple Sclerosis
Untitled-1 (1)
Structure-Guided Development of Deoxycytidine Kinase Inhibitors with Nanomolar Affinity and Improved Metabolic Stability
Untitled-1 (1)
Deoxycytidine Kinase Augments ATM-Mediated DNA Repair and Contributes to Radiation Resistance
Untitled-1 (1)
Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress
Untitled-1 (1)
Novel Positron Emission Tomography Probes Specific for Deoxycytidine Kinase
View More Posts
Facebook-f X-twitter Youtube Linkedin-in Instagram
Featured Posts
Picture_trethera1
Featured News
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress
AdobeStock_704757454 (1)
Featured News
Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
AdobeStock_704757454 (1)
Featured News
Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients
Join us in our journey as we pursue life changing treatments.
Trethera

Copyright © 2025 Trethera. All Rights Reserved. Trethera and other trademarks, service marks, and designs are the registered or unregistered trademarks of Trethera in the United States and other countries. TRE-515 has not been FDA approved and is currently in clinical trials.

Scroll to Top
Get In Touch With Trethera

Your feedback is very important to us. We will get back to you within 48 hours.

13547 Ventura Boulevard,
Suite 363
Sherman Oaks, CA 91423

For inquiries about access to our investigational medical products outside of clinical trials, please visit our Expanded Access Policy.